A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors
What is the purpose of this trial?
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib.
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date06/14/2022
- End Date11/15/2023
- Last Updated07/14/2022
- Study HIC#2000029048